Literature DB >> 3922294

Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model.

J Blaser, B B Stone, S H Zinner.   

Abstract

Several aminoglycoside dosage regimens were studied in a kinetic in vitro model. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus were exposed in serially placed artificial capillary units to netilmicin concentrations that changed based on human two-compartment pharmacokinetics. The same total dose per 24 h was administered as a continuous infusion (3.7 micrograms/ml) or in 1-h infusions given every 24 (24 micrograms/ml) or 8 h (8 micrograms/ml). The once daily administration showed the best response in terms of either faster killing of E. coli, K. pneumoniae, and S. aureus or greater reduction of the inocula of P. aeruginosa. After 28 h of treatment, however, all regimens reduced the nonpseudomonads by more than 99.99%, whereas all three P. aeruginosa strains regrew to greater than 10(8) CFU/ml due to selection of resistant subpopulations. In contrast to the bactericidal effect of the first dose, no killing occurred after subsequent doses if the ratio of peak drug concentration to MIC was low (less than or equal to 6). These results support the concept of administering high doses of aminoglycosides once every 24 h.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922294      PMCID: PMC176274          DOI: 10.1128/AAC.27.3.343

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy.

Authors:  H EAGLE; R FLEISCHMAN; M LEVY
Journal:  N Engl J Med       Date:  1953-03-19       Impact factor: 91.245

2.  Infections in cancer patients. Results with gentamicin sulfate therapy.

Authors:  G P Bodey; E Middleman; T Umsawadi; V Rodriguez
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

3.  Biological variability of multiple dose pharmacokinetics of netilmicin in man.

Authors:  J Blaser; H Rieder; P Niederer; R Lüthy
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Pseudomonas bacteremia. Review of 108 cases.

Authors:  M R Flick; L E Cluff
Journal:  Am J Med       Date:  1976-04       Impact factor: 4.965

5.  New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.

Authors:  S Grasso; G Meinardi; I de Carneri; V Tamassia
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

6.  Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice.

Authors:  A U Gerber; W A Craig; H P Brugger; C Feller; A P Vastola; J Brandel
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

7.  Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin.

Authors:  A M Lerner; M P Reyes; L A Cone; D C Blair; W Jansen; G E Wright; R R Lorber
Journal:  Lancet       Date:  1983-05-21       Impact factor: 79.321

8.  Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin.

Authors:  S H Powell; W L Thompson; M A Luthe; R C Stern; D A Grossniklaus; D D Bloxham; D L Groden; M R Jacobs; A O DiScenna; H A Cash; J D Klinger
Journal:  J Infect Dis       Date:  1983-05       Impact factor: 5.226

9.  A comparative trial of sisomicin therapy by intermittent versus continuous infusion.

Authors:  R Feld; M Valdivieso; G P Bodey; V Rodriguez
Journal:  Am J Med Sci       Date:  1977 Sep-Oct       Impact factor: 2.378

10.  Antimicrobial activity of netilmicin in comparison with gentamicin, sisomicin, tobramycin, and amikacin and their resistance patterns.

Authors:  I Braveny; J Voeckl; K Machka
Journal:  Arzneimittelforschung       Date:  1980
View more
  26 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

Review 2.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Serum bactericidal activity and killing rate for volunteers receiving imipenem, imipenem plus amikacin, and ceftazidime plus amikacin against Pseudomonas aeruginosa.

Authors:  P Van der Auwera; J Klastersky; H Lagast; M Husson
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

4.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

5.  Net effect of inoculum size on antimicrobial action of ampicillin-sulbactam: studies using an in vitro dynamic model.

Authors:  A A Firsov; M Ruble; D Gilbert; D Saverino; D Savarino; B Manzano; A A Medeiros; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits.

Authors:  M G Täuber; S Kunz; O Zak; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 8.  Once-daily aminoglycoside administration: new strategies for an old drug.

Authors:  J M Kovarik; I M Hoepelman; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-09       Impact factor: 3.267

9.  Gentamicin concentrations in human subcutaneous tissue.

Authors:  H Lorentzen; F Kallehave; H J Kolmos; U Knigge; J Bülow; F Gottrup
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.

Authors:  A A Firsov; D Saverino; D Savarino; M Ruble; D Gilbert; B Manzano; A A Medeiros; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.